Michael Burkes Brophy Sells 2,413 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,413 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were sold at an average price of $237.56, for a total transaction of $573,232.28. Following the transaction, the chief financial officer directly owned 60,926 shares of the company’s stock, valued at $14,473,580.56. This represents a 3.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $230.40, for a total value of $430,156.80.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total value of $5,621,553.52.

Natera Price Performance

Natera stock opened at $231.14 on Friday. Natera, Inc. has a 52-week low of $125.38 and a 52-week high of $256.36. The firm has a market capitalization of $31.97 billion, a P/E ratio of -100.93 and a beta of 1.62. The stock has a fifty day moving average price of $235.91 and a two-hundred day moving average price of $193.80.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s quarterly revenue was up 34.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

Institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC boosted its position in Natera by 6.6% during the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after purchasing an additional 96 shares during the period. NewEdge Advisors LLC increased its stake in Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after acquiring an additional 1,847 shares during the period. Focus Partners Wealth raised its stake in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Natera in the 2nd quarter valued at about $298,000. Finally, Signaturefd LLC increased its stake in Natera by 10.0% in the second quarter. Signaturefd LLC now owns 1,620 shares of the medical research company’s stock valued at $274,000 after acquiring an additional 147 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on NTRA shares. Wells Fargo & Company upped their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. TD Cowen restated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. Barclays boosted their price target on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Evercore ISI boosted their price objective on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Citigroup initiated coverage on shares of Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.20.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.